Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Friedman

Showing results (1311-1320 of 1,475) with videos related to

Pageof 148
Sort By:
Cancer|December 24, 2009
Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant gliomaLee W Jones, Allan H Friedman, Miranda J West, et al.
Journal of Neuropathology and Experimental Neurology|December 1, 2018
MGMT: Immunohistochemical Detection in High-Grade AstrocytomasEric S Lipp, Patrick Healy, Alan Austin, et al.
Health Research Policy and Systems|June 30, 2017
Building capacity for information and communication technology use in global health research and training in China: a qualitative study among Chinese health sciences faculty membersJie Wang, Abu S Abdullah, Zhenyu Ma, et al.
Neuro-Oncology|March 28, 2002
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experienceChristopher D Turner, Sridharan Gururangan, James Eastwood, et al.
Cancer Research|March 17, 2006
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant gliomaPeter E Fecci, Duane A Mitchell, John F Whitesides, et al.
Annals of Neurology|March 1, 1994
Neuronal migration disorders: positron emission tomography correlationsN Lee, R A Radtke, L Gray, et al.
Cancer|May 4, 2001
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case studyI Cokgor, G Akabani, H S Friedman, et al.
Immunogenetics|January 1, 1991
HLA antigens and risk for development of pemphigus foliaceus (fogo selvagem) in endemic areas of BrazilJ R Moraes, M E Moraes, M Fernandez-Vina, et al.
International Journal of Radiation Oncology, Biology, Physics|April 7, 1999
There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapyL R Mandell, R Kadota, C Freeman, et al.
Journal of Neuro-Oncology|January 1, 1995
Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary reportD D Bigner, M Brown, R E Coleman, et al.
Pageof 148

Showing results (1311-1320 of 1,475) with videos related to

Sort By:
Pageof 148
Cancer|December 24, 2009
Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant gliomaLee W Jones, Allan H Friedman, Miranda J West, et al.
Journal of Neuropathology and Experimental Neurology|December 1, 2018
MGMT: Immunohistochemical Detection in High-Grade AstrocytomasEric S Lipp, Patrick Healy, Alan Austin, et al.
Health Research Policy and Systems|June 30, 2017
Building capacity for information and communication technology use in global health research and training in China: a qualitative study among Chinese health sciences faculty membersJie Wang, Abu S Abdullah, Zhenyu Ma, et al.
Neuro-Oncology|March 28, 2002
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experienceChristopher D Turner, Sridharan Gururangan, James Eastwood, et al.
Cancer Research|March 17, 2006
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant gliomaPeter E Fecci, Duane A Mitchell, John F Whitesides, et al.
Annals of Neurology|March 1, 1994
Neuronal migration disorders: positron emission tomography correlationsN Lee, R A Radtke, L Gray, et al.
Cancer|May 4, 2001
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case studyI Cokgor, G Akabani, H S Friedman, et al.
Immunogenetics|January 1, 1991
HLA antigens and risk for development of pemphigus foliaceus (fogo selvagem) in endemic areas of BrazilJ R Moraes, M E Moraes, M Fernandez-Vina, et al.
International Journal of Radiation Oncology, Biology, Physics|April 7, 1999
There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapyL R Mandell, R Kadota, C Freeman, et al.
Journal of Neuro-Oncology|January 1, 1995
Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary reportD D Bigner, M Brown, R E Coleman, et al.
Pageof 148